Citations 66

PET/MRI: Where might it replace PET/CT?

Journal of Magnetic Resonance Imaging | March 31, 2017 | Volume: 46 | Issue: 5 | Pages: 1247-1262

10.1002/jmri.25711 | PMID 28370695

Simultaneous positron emission tomography and MRI (PET/MRI) is a technology that combines the anatomic and quantitative strengths of MR imaging with physiologic information obtained from PET. PET and computed tomography (PET/CT) performed in a single scanning session is an established technology already in widespread and accepted use worldwide. Given the higher cost and complexity of operating and interpreting the studies obtained on a PET/MRI system, there has been question as to which patients would benefit most from imaging with PET/MRI versus PET/CT. In this article, we compare PET/MRI with PET/CT, detail the applications for which PET/MRI has shown promise and discuss impediments to future adoption. It is our hope that future work will prove the benefit of PET/MRI to specific groups of patients, initially those in which PET/CT and MRI are already performed, leveraging simultaneity and allowing for greater degrees of multiparametric evaluation.Level of Evidence: 5Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2017;46:1247–1262.
Detection of ALECT2 amyloidosis by positron emission tomography–computed tomography imaging with florbetapir

British Journal of Haematology | January 20, 2017 | Volume: 177 | Issue: 1 | Pages: 12-12

10.1111/bjh.14519 | PMID 28107549

First PET Imaging Studies With 63 Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease

Molecular Imaging | December 10, 2016 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/1536012116673793 | PMID 27941122

Abnormalities in zinc homeostasis are indicated in many human diseases, including Alzheimer disease (AD). 63 Zn-zinc citrate was developed as a positron emission tomography (PET) imaging probe of zinc transport and used in a first-in-human study in 6 healthy elderly individuals and 6 patients with clinically confirmed AD. Dynamic PET imaging of the brain was performed for 30 minutes following intravenous administration of 63 Zn-zinc citrate (∼330 MBq). Subsequently, body PET images were acquired. Urine and venous blood were analyzed to give information on urinary excretion and pharmacokinetics. Regional cerebral 63 Zn clearances were compared with 11 C-Pittsburgh Compound B ( 11 C-PiB) and 18 F-fluorodeoxyglucose ( 18 F-FDG) imaging data. 63 Zn-zinc citrate was well tolerated in human participants with no adverse events monitored. Tissues of highest uptake were liver, pancreas, and kidney, with moderate uptake being seen in intestines, prostate (in males), thyroid, spleen, stomach, pituitary, and salivary glands. Moderate brain uptake was observed, and regional dependencies were observed in 63 Zn clearance kinetics in relationship with regions of high amyloid-β plaque burden ( 11 C-PiB) and 18 F-FDG hypometabolism. In conclusion, zinc transport was successfully imaged in human participants using the PET probe 63 Zn-zinc citrate. Primary sites of uptake in the digestive system accent the role of zinc in gastrointestinal function. Preliminary information on zinc kinetics in patients with AD evidenced regional differences in clearance rates in correspondence with regional amyloid-β pathology, warranting further imaging studies of zinc homeostasis in patients with AD.
Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging

JAMA Cardiology | August 24, 2016 | Volume: 1 | Issue: 8 | Pages: 880

10.1001/jamacardio.2016.2839 | PMID 27557400

Multimodality Imaging of Neurodegenerative Processes: Part 2, Atypical Dementias

American Journal of Roentgenology | August 9, 2016 | Volume: 207 | Issue: 4 | Pages: 883-895

10.2214/ajr.14.12910 | PMID 27504528

Multimodality Imaging of Neurodegenerative Processes: Part 1, The Basics and Common Dementias

American Journal of Roentgenology | August 9, 2016 | Volume: 207 | Issue: 4 | Pages: 871-882

10.2214/ajr.14.12842 | PMID 27505704

Pseudomyxoma Pleuri. A Rare Manifestation of an Uncommon Disease

American Journal of Respiratory and Critical Care Medicine | June 2, 2015 | Volume: 191 | Issue: 11 | Pages: 1334-1335

10.1164/rccm.201412-2246im | PMID 26029839

Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis

American Journal of Respiratory and Critical Care Medicine | October 31, 2014 | Volume: 190 | Issue: 9 | Pages: 1069-1071

10.1164/rccm.201407-1258le | PMID 25360730

Pulmonary masses in a patient with dyspnea: Apply Occam's razor or Hickam's dictum?

American Journal of Hematology | October 9, 2014 | Volume: 90 | Issue: 5 | Pages: 462-465

10.1002/ajh.23870 | PMID 25297538

Cutting Edge: An Endogenous Pathway to Systemic Inflammatory Response Syndrome (SIRS)-Like Reactions through Toll-Like Receptor 4

The Journal of Immunology | April 20, 2014 | Volume: 172 | Issue: 1 | Pages: 20-24

10.4049/jimmunol.172.1.20 | PMID 14688304

Abstract Systemic inflammatory response syndrome (SIRS) is typically associated with trauma, surgery, or acute pancreatitis. SIRS resembles sepsis, triggered by exogenous macromolecules such as LPS acting on Toll-like receptors. What triggers SIRS in the absence of infection, however, is unknown. In this study, we report that a SIRS-like response can be induced in mice by administration of soluble heparan sulfate, a glycosaminoglycan associated with nucleated cells and extracellular matrices, and by elastase, which cleaves and releases heparan sulfate proteoglycans. The ability of heparan sulfate and elastase to induce SIRS depends on functional Toll-like receptor 4, because mutant mice lacking that receptor or its function do not respond. These results provide a molecular explanation for the initiation of SIRS.